TY - JOUR
T1 - Current mamangementof secondary hyperparathyroidism: a multicenter observational study (COSMOS)
AU - Cannata-Andia, Jorge
AU - Fernandez-Martin, Jl
AU - Zoccali, Carmine
AU - London, Gerard
AU - Locatelli, Francesco
AU - Ketteler, Markus
AU - Ferreira, Anibal
AU - Covic, Adrian
AU - Floege, Jürgen
AU - Gorriz, José Luis
AU - Rutkowski, Boleslaw
AU - Memmos, Dimitrios
AU - Verbeelen, Dierik
AU - Tielemans, Christian
AU - Teplan, Vladimir
AU - Bos, Willem Jan
AU - Nagy, Judit
AU - Kramar, Reinhart
AU - Goldsmith, David
AU - Martin, Pierre-Yves
AU - Wüthrich, Rudolf
AU - Pavlovic, Drasko
AU - Benedik, Mihael
PY - 2008
Y1 - 2008
N2 - Study aims: To survey bone mineral disturbances in the hemodialysis (HD) population in Europe and current clinical practice in Europe for the prevention, diagnosis and treatment of secondary hyperparathyroidism (SHPT) in HD patients. Primary objectives: First, to estimate the prevalence of Kidney Disease Outcomes Quality Initiative (K/DOQI) guideline achievement in a representative sample of European hemodialysis subjects. As part of this objective, we will investigate the prevalence of achievement by type of dialysis, type of center and time on dialysis (less than or greater than 1 year). Among new dialysis subjects (less than 1 year), we will evaluate prevalence of K/DOQI target achievement until the end of the study. The study will run for 3 years. Second, to estimate the association of bone mineral markers (parathyroid hormone [PTH], calcium [Ca], serum phosphorus [P] and calcium phosphate product [Ca×P]) classified by achievement of K/DOQI targets with mortality and overall cardiovascular hospitalization. Third, to characterize the longitudinal changes in bone mineral markers. As part of this objective, we will describe the patterns and predictors of bone mineral markers and achievement, with K/DOQI targets, using repeated measurements on individuals over time. Secondary objectives: First, To estimate the association of bone mineral markers (PTH, Ca, P and Ca×P) classified by achievement of K/DOQI targets with specific cardiovascular outcomes, parathyroidectomy, manifest bone disease (including incidence of symptomatic bone fractures), hospitalizations and vascular access. Second, to evaluate the additional value of albumin and hemoglobin levels in conjunction with bone mineral markers in the prediction of mortality and clinical events.
AB - Study aims: To survey bone mineral disturbances in the hemodialysis (HD) population in Europe and current clinical practice in Europe for the prevention, diagnosis and treatment of secondary hyperparathyroidism (SHPT) in HD patients. Primary objectives: First, to estimate the prevalence of Kidney Disease Outcomes Quality Initiative (K/DOQI) guideline achievement in a representative sample of European hemodialysis subjects. As part of this objective, we will investigate the prevalence of achievement by type of dialysis, type of center and time on dialysis (less than or greater than 1 year). Among new dialysis subjects (less than 1 year), we will evaluate prevalence of K/DOQI target achievement until the end of the study. The study will run for 3 years. Second, to estimate the association of bone mineral markers (parathyroid hormone [PTH], calcium [Ca], serum phosphorus [P] and calcium phosphate product [Ca×P]) classified by achievement of K/DOQI targets with mortality and overall cardiovascular hospitalization. Third, to characterize the longitudinal changes in bone mineral markers. As part of this objective, we will describe the patterns and predictors of bone mineral markers and achievement, with K/DOQI targets, using repeated measurements on individuals over time. Secondary objectives: First, To estimate the association of bone mineral markers (PTH, Ca, P and Ca×P) classified by achievement of K/DOQI targets with specific cardiovascular outcomes, parathyroidectomy, manifest bone disease (including incidence of symptomatic bone fractures), hospitalizations and vascular access. Second, to evaluate the additional value of albumin and hemoglobin levels in conjunction with bone mineral markers in the prediction of mortality and clinical events.
KW - calcium
KW - survey
KW - parathyroid hormone
M3 - Article
VL - 21
SP - 290
EP - 298
JO - Journal of Nephrology
JF - Journal of Nephrology
SN - 1121-8428
IS - 3
ER -